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Although variousfunctionofchemerinhavebeensuggested,itsphysiologicalroleremainstobeelucidated.
Here we show that chemerin-deficient mice are glucose intolerant irrespective of exhibiting reduced
macrophage accumulation in adipose tissue. The glucose intolerance was mainly due to increased hepatic
glucose production and impaired insulin secretion. Chemerin and its receptor ChemR23 were expressed in
b-cell. Studies using isolated islets and perfused pancreas revealed impaired glucose-dependent insulin
secretion(GSIS)inchemerin-deficientmice.Conversely,chemerintransgenicmicerevealedenhancedGSIS
andimprovedglucosetolerance.ExpressionofMafA,apivotaltranscriptionalfactorforb-cellfunction,was
downregulated in chemerin-deficient islets and a chemerin-ablated b-cell line and rescue of MafA
expression restored GSIS, indicating that chemerin regulates b-cell function via maintaining MafA
expression. These results indicate that chemerin regulates b-cell function and plays an important role in
glucose homeostasis in a tissue-dependent manner.
T
ype-2 diabetes is an emerging health hazard worldwide and contributes to increased morbidity and mor-
tality. It results from the development of insulin resistance and a concomitant impairment of insulin
secretion. Particularly for the onset of the disease, impaired insulin secretion is an essential factor. Under
these conditions, adipokines secreted from the adipose tissue play a pivotal role
1,2. Adipokines such as leptin,
adiponectin, and resistin, regulate energy and glucose homeostasis. Adipocytes also secrete inflammatory cyto-
kines, such as tumor necrosis factor-a, interleukin-6 and monocyte chemotactic protein-1 (MCP-1) that are
classically considered to be produced by macrophages, and link inflammation and insulin resistance
3,4. These
adipokines exert their effects in an endocrine, autocrine, or paracrine manner and regulate metabolism.
Chemerin was originally identified in the skin as tazarotene-induced gene 2 (TIG2)
5. It is a chemotactic
substancethatwasidentifiedastheligandforanorphanGprotein-coupledreceptor,ChemR23/CMKLR1,which
shares a similarity to chemokine receptor and is expressed in immature dendritic cells (DCs) and macrophages
6.
Chemerin promotes chemotaxis of DCs and macrophages
6, suggesting that chemerin is associated with a pro-
inflammatory state like other chemokines. On the other hand, ChemR23-deficient mice treated with LPS exhibit
greater neutrophil and macrophage recruitment into lung tissue than wild type mice, suggesting that chemerin
has an anti-inflammatory function
7. Importantly, ChemR23-deficient mice are unresponsive to chemerin, indi-
cating that the chemerin/ChemR23 system plays anti-inflammatory role, and that ChemR23 is the physiological
receptor for chemerin
7,8. Recently, it has been reported that CCRL2 and GPR1 may also serve as receptors for
chemerin. However, CCRL2 does not transduce signals intocells
9.Furthermore, chemerin-inducedCa mobilisa-
tion via GPR1 is much lower than that of ChemR23
10. Thus far, the physiological relevance of these receptors in
chemerin function remains unknown.
Recently, several groups have reported that chemerin is an adipokine
11–14 that regulates adipocyte differenti-
ationandlipolysis
11,13.Furthermore,chemerinenhancesinsulin-dependentglucoseuptakeinadipocytes
14.These
data suggest that chemerin functions as an adipokine in metabolic regulation. Indeed, serum chemerin levels are
associatedwithBMI,fastingglucose,seruminsulin,plasmatriglycerides,andserumcholesterollevels
12.However,
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study, we investigated the role of chemerin in glucose homeostasis
particularly in b-cells using chemerin-deficient and transgenic mice.
Results
Generationofchemerin-deficientmice.Toclarifythephysiological
role of chemerin, we generated chemerin-deficient mice by targeted
gene deletion (Supplementary Fig. 1a). The chemerin (2/2) mice
showed grossly normal and were fertile. The chemerin (1/1) and
(2/2) mice gained weights similarly (Supplementary Fig. 2a). Food
intake was not significantly different in chemerin (1/1) and (2/2)
mice (Supplementary Fig. 2b). Serum cholesterol and triglyceride
levels in chemerin (2/2) mice were comparable to those of the
(1/1) mice (Supplementary Fig. 2c, d). However, the serum levels
ofnon-esterifiedfattyacid(NEFA,free-fattyacids)weresignificantly
lower in (2/2) mice than in (1/1) mice (Supplementary Fig. 2e).
Impaired glucose homeostasis inchemerin-deficient mice.Several
reports have suggested that chemerin plays a role in glucose home-
ostasisinvitro
14,15andinvivo
16,thereforeweexaminedglucosemeta-
bolism in chemerin (2/2) mice using the intraperitoneal glucose
tolerance test (IPGTT). Although the fasting glucose levels were
comparable in chemerin (1/1) and (2/2) mice, the blood glucose
levels at 15, 30, 60, and 90 min after intraperitoneal glucose admin-
istration were significantly higher in chemerin (2/2) mice than in
chemerin (1/1) mice (Fig. 1a), indicating that chemerin deficiency
leads to impaired glucose tolerance. To further define the tissue-
specific alterations in glucose metabolism in chemerin (2/2) mice,
we performed euglycemic hyperinsulinemic clamp studies. The glu-
cose infusion rate (GIR) was not significantly altered (Fig. 1b), indi-
cating that the net insulin sensitivity was comparable in chemerin
(1/1) and (2/2) mice. The glucose disappearance rate (Rd) was
significantlyincreased inthe(2/2) mice,indicating enhancedmus-
cle glucose uptake (Fig. 1c). Although basal hepatic glucose produc-
tion (BHGP) was not different (Fig. 1d), clamp hepatic glucose
production (CHGP) was significantly higher in (2/2) mice than
in (1/1) mice (Fig. 1e), indicating that insulin suppression of hep-
aticglucoseproductionwasimpairedinchemerin(2/2)mice.Liver
weight and histological analyses revealed no obvious differences
between chemerin (1/1) and (2/2) mice (Fig. 1f, g). We further
analyzed the expression of G6Pase and PEPCK, which are the main
regulators of gluconeogenesis in the liver. Consistent with increased
CHGP, the abundance of G6Pase and PEPCK mRNAs were signifi-
cantly higher in the liver of chemerin (2/2) mice than in those of
chemerin (1/1) mice (Fig. 1h). Furthermore, the transcriptional
coactivator PGC-1a mRNA was upregulated in chemerin (2/2)
mice (Fig. 1h). These data indicate that chemerin deficiency
enhancedmuscleglucoseuptakeandincreasedhepaticgluconeogen-
esis in vivo. Then, as a measure of insulin downstream signaling, we
examined Akt phosphorylation in muscle and adipose tissue.
Consistentwiththeresultsoftheclampstudies,Aktphosphorylation
wasenhancedinthegastrocnemiusmuscleunderinsulin-stimulated
conditions (Fig. 1i). In contrast, insulin-stimulated Akt phosphory-
lation was decreased in the epididymal fat (Fig. 1j).
Macrophage infiltration into adipose tissueof chemerin-deficient
mice. It has been demonstrated that chemerin regulates adipocyte
differentiationandfunction.Wenextexaminedthecharacteristicsof
adiposetissueinchemerin(2/2)mice.Therewerenodifferencesin
epididymal fat weight between chemerin (1/1) and (2/2) mice
(Fig. 2a). Histological analyses of epididymal fat revealed no obvious
differences(Fig.2b).Further,weexaminedtheexpressionofmarkers
of adipose tissue differentiation, function, and inflammation. There
were no obvious differences in the expression of differentiation
markers; however, the expression of macrophage markers, CD68
and F4/80, were significantly downregulated in chemerin (2/2)
mice (Fig. 2c). Comparably, the number of Mac3-positive cells in
the adipose tissue was significantly reduced (Fig. 2d, e), suggesting
that macrophage infiltration was suppressed in chemerin (2/2)
mice.Serumleptinandadiponectinconcentrationswerecomparable
in chemerin (1/1) and (2/2) mice (Fig. 2f).
ChemerinanditsreceptorChemR23areexpressedinb2cells.The
results of euglycemic hyperinsulinemic clamp studies suggested that
impaired insulin secretion, and not insulin resistance, may be the
predominant cause of glucose intolerance in chemerin (2/2) mice.
First, we examined the expression of chemerin, its receptor
ChemR23, and putative receptors GPR1 and CCRL2 in various tis-
sues, including the pancreas. Intriguingly, chemerin was strongly
expressed in the human pancreas (Fig. 3a). ChemR23 was predomi-
nantly expressed in WAT, heart, and testis (Fig. 3b). GPR1 was
ubiquitously expressed but a relatively high expression was observed
in WAT, BAT, and heart (Fig. 3c). CCRL2 was predominantly
expressedintheheart(Fig.3Dd).Wefurtheranalyzedtheexpression
of these receptors in the pancreas using immunohistochemistry. In
the pancreas, ChemR23 and GPR1 were expressed in the islets, in
contrasttothescantexpression ofCCRL2(Supplementary Figu.3a).
Because ChemR23 has been shown to be the physiological receptor
for chemerin
7,17, we examined the expression of ChemR23 and che-
merin in greater detail. ChemR23 and chemerin were exclusively
detected in the b-cells of the islet as compared to insulin (Fig. 3e).
Then, weexamined the expression of ChemR23 and chemerin in the
pancreas of obese and diabetic mouse models. Although there were
no obvious changes in the expression of ChemR23 mRNA in these
mouse models (Fig. 3f), the expression of chemerin was significantly
downregulated in db/db mice and streptozotocin (STZ)-treated dia-
betic mice (Fig. 3g). Immunohistochemical analysis revealed that,
similar to mRNA, the expression of chemerin was downregulated
in the islet of db/db and STZ mice (Supplementary Fig. 3b).
Interestingly, the expression of ChemR23 was downregulated
in HFD, db/db, and STZ mice, suggesting the presence of regula-
tory mechanisms at the protein level (Supplementary Fig. 3b).
Furthermore, the expression of ChemR23 was severely impaired in
chemerin (2/2) mice, suggesting that chemerin itself may regulate
the expression of its receptor (Fig. 3h).
Chemerin-deficient b2cells exhibit impaired glucose-stimulated
insulin secretion. The expression and regulation of ChemR23 and
chemerin in b-cells suggest that b-cell may be a direct target
for chemerin. First, we analyzed the morphology of the islets in the
chemerin (2/2) mice, and detected no obvious morphological
changes in the islets (Fig. 4a); no significant differences were
observed in the islet areas of chemerin (1/1) and (2/2) mice
(Fig. 4b). Then we analyzed the insulin secretion ability of chemerin
(2/2) mice in detail. Indeed, serum insulin levels were significantly
lower in the chemerin (2/2) mice 30 min after intraperitoneal glu-
coseadministration(Fig.4c).Further,weexaminedinsulinsecretion
in response to glucose in the islets in vitro. Interestingly, in response
to 16.7mM glucose, the isolated islets of (2/2) mice exhibited a
marked decrease in insulin secretion compared to those of (1/1)
mice (Fig 4d, Supplementary Fig. 4a). There were no differences in
the insulin content of (1/1) and (2/2) islets (Fig. 4e). To evaluate
the insulin secretion ability in vivo, we analyzed insulin secretion in
perfused pancreas. As shown in Figure 4f, perfusion with 16.7 mM
glucose elicited substantial insulin secretion in (1/1) mice. In con-
trast, insulin secretion was significantly reduced in the littermate
(2/2) mice. The area under the curve (%AUC) for insulin during
glucose stimulation was significantly reduced in the (2/2) mice
(Fig. 4g). In response to KCl, a potent secretagogue of insulin secre-
tion, the (2/2) pancreata exhibited a significant decrease in insulin
secretion compared to the controls (Fig. 4h). These results indicate
that the insulin-secretion capability of b-cells was impaired in che-
merin (2/2) mice. To determine whether the action of chemerin
www.nature.com/scientificreports
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revealed that ChemR23 was substantially expressed in MIN6 cells
(Fig. 4i). The expression of chemerin and ChemR23 protein wasalso
detected in MIN6 cells (Figure 4j). To explore the role of chemerin
and ChemR23 in GSIS in MIN6 cells, we performed knockdown
experiments (Fig. 4j, Supplementary Fig. 4b, c). Consistent with
the results from chemerin (2/2) mice, knockdown of chemerin or
ChemR23 in MIN6 cells led to impaired GSIS (Fig. 4k).
Theeffectofahighfatdiet(HFD)onchemerin-deficientmiceand
GSISinchemerin-transgenicmice.WeexaminedtheeffectofHFD
onchemerin(2/2)mice.After6weeksofHFD,althoughwedidnot
detect significant differences in thebody weightsof chemerin (1/1)
and (2/2) mice (Fig. 5a), glucose intolerance deteriorated (Fig. 5b)
and insulin secretion tended to decrease in chemerin (2/2) mice at
30 min after intraperitoneal glucose administration (Fig. 5c). To
examine the effect of chemerin overexpression in vivo, we generated
Figure 1 | Chemerin-deficient mice exhibit impaired glucose tolerance and enhanced glucose production in the liver. (a) Intraperitoneal glucose
tolerance test in 12-week-old chemerin (1/1) and (2/2) mice. (n 5 5–6/genotype). (b) Glucose infusion rate (GIR) at steady-state blood glucose,
a measure of general insulin sensitivity, was determined by euglycemic clamp studies. Ten to 14 week-old mice were used for these studies.
(n56/genotype).(c)Steady-stateglucosedisposablerate(Rd),ameasureofinsulin-dependentglucoseuptakeinthemuscle,wascalculatedasdescribed
in Supplementary Methods. (d) Basal hepatic glucose production. (e) Clamp hepatic glucose production at the steady-state were calculated. (f) Liver
weightsof10week-oldchemerin(1/1)and(2/2)mice.(g)H&Esectionsofliverinchemerin(1/1)and(2/2)mice.(4003)(h)Relativeexpression
of genes related to glucose production in mice liver during steady-state conditions in clamp studies using quantitative real-time PCR. (n 5 6/genotype).
(i,j)Activationofinsulinsignalingingastrocnemiusmuscle(i)andepididymalfat(j)of12-week-oldchemerin(1/1)and(2/2)mice.Insulinatadose
of 10 U/kg was intraperitoneally administered, and the mice were sacrificed 15 min later. Lysates of indicated tissues were subjected to immunoblotting
analysis for Ser473-phosphorylated forms of Akt. (n 5 3/genotype).
www.nature.com/scientificreports
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mice(SupplementaryFig.1g,h),inwhichchemerinisoverexpressed
intheliver.Weusedthispromoterbecauseliveristhemostabundant
tissue for chemerin expression (Fig 3a). We obtained 2 transgenic
micelines,(Tg1andTg2).Immunoblottinganalysisrevealedthatthe
serum chemerin levels were 1.9- fold and 7.2- fold higher in Tg1 and
Tg2 mice, respectively, than in wild-type mice (Fig. 5d, e). We then
performed the glucose tolerance test, and analyzed insulin secretion
in Tg1mice. Consistent with the results fromchemerin (2/2) mice,
chemerin transgenic mice exhibited improved glucose tolerance
(Fig. 5f) and enhanced GSIS 15 and 30 min after intraperitoneal
glucose administration than in wild-type mice (Fig. 5g).
Chemerin regulates GSIS by maintaining MafA expression in
b2cells. To dissect the molecular mechanisms by which chemerin
regulates b-cell function, we compared the expression of genes that
regulate b-cell function in islets isolated from chemerin (1/1) and
(2/2) mice. Although most of the genes exhibited no changes in
expression, MafA was significantly downregulated (by 53%) in the
islets of (2/2) mice (Fig. 6a, Supplementary Fig. 4d). Furthermore,
the expression of Glut2 was also significantly downregulated in the
islets of (2/2) mice. The protein levels of MafA were lower in the
chemerin (2/2) islets (Fig. 6b, c). Immunohistochemical analysis
revealed that the MafA nuclear staining in (2/2) islets was substan-
tially weaker than that of chemerin (1/1) islet (Fig. 6d). Further, we
analyzed whether knockdown of chemerin or ChemR23 in MIN6
cells reduced MafA expression in vitro. Expectedly, MafA expression
was downregulated in chemerin- and ChemR23-knockdown MIN6
cells (Fig. 6e, f). These data suggest that chemerin and ChemR23 are
necessary for MafA expression in b-cells. To clarify the functional
relevance of the changes in MafA expression in chemerin (2/2)
b-cells, we rescued MafA expression (Supplementary Fig. 4e) in the
isolated islets (Fig. 6g) and MIN6 cells (Fig. 6i) using adenovirus.
AlthoughoverexpressionofMafAdidnotaffectGSISintheisletsfrom
Figure 2 | Phenotypicanalysis ofadipose tissuein chemerin-deficient mice. (a)Weights ofepididymal fat in10-week-old chemerin (1/1)and (2/2)
mice. (b) H&E sections of epididymal fat tissue from chemerin (1/1) and (2/2) mice. (1003) (c) Expression of adipocyte markers in epididymal
adipose tissue. (n 5 4–5/genotype). (d) Immunohistochemical detection of Mac3 in epididymal adipose tissue of 10-week-old (1/1) and (2/2) mice.
Macrophages are stained brown. (4003) (e) Macrophage infiltration into epididymal fat tissue was quantified as the ratio of Mac3-positive cells to total
cells.Dataaremean6SEM.(n53/genotype).(f)Serumleptinandadiponectinconcentrationsinchemerin(1/1)and(2/2)mice.(n56/genotype).
www.nature.com/scientificreports
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(2/2) mice partially but significantly improved the impaired GSIS
(Fig. 6h). Further, the rescue of MafA expression in chemerin-ablated
MIN6 cells also significantly improved GSIS (Figure 6 j).
Discussion
We have shown that chemerin (2/2) mice exhibit glucose intol-
erance. The glucose clamp studies using chemerin (2/2) mice
demonstrated that chemerin regulates hepatic glucose production
and muscle glucose uptake. GSIS was impaired in chemerin (2/2)
mice, indicating that chemerin is involved in insulin secretion as
well as in insulin sensitivity. These results indicate that chemerin
playsanimportantroleinglucosehomeostasisinatissue-dependent
manner. We demonstrated that ChemR23 and chemerin are
substantially expressed in b-cells and chemerin is necessary for
insulin secretion in b-cells in vitro and vivo. Conversely, the
improved glucose tolerance and enhanced insulin secretion
observedinchemerintransgenicmice furthersupport thatchemerin
Figure 3 | Chemerin and its receptor expression in b- cells. (a) Northern blotting analysis of chemerin in human tissues. Relative mRNA expression of
(b)ChemR23,(c)GPR1,and(d)CCRL2inmousetissuesevaluatedbyquantitativerealtimePCRanalysis(QRPCR).(e)Immunofluorescenceanalysisof
thechemerin receptor,ChemR23,chemerinandinsulininthemouseislets.(f)QRPCRanalysisofChemR23andchemerin expressionsinpancreasfrom
HFD-fed mice, db/db mice, and streptozotocin (STZ)-induced diabetic mice. (n 5 4/group). (h) Immunofluorescence analysis of ChemR23 and insulin
in chemerin (1/1) and (2/2) islets.
www.nature.com/scientificreports
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systemically circulating or locally secreted chemerin is important
for the regulation of b-cells, the observation that chemerin
expression in b-cells is regulated depending on the metabolic status,
suggests that locally produced chemerin may function in an auto-
crine/paracrine manner.
With respect to the mechanism in b-cells, we have shown that
MafA expression is regulated by chemerin in vitro and in vivo.
Figure 4 | Impaired glucose-stimulated insulin secretion (GSIS) in chemerin-deficient pancreas, islets and MIN6 cells. (a) Histological analysis of
pancreasbyH&Estaininginchemerin(1/1)and(2/2)mice.Representativeimagesareshown.(b)Percentisletareain15-week-old(1/1)and(2/2)
mice. (n 5 4/genotype). (c) Serum insulin levels after glucose administration in 14-week-old mice. (n 5 6/genotype). (d) Insulin secretion in islets
isolatedfromat12-14week-old(1/1)and(2/2)mice.(n56/genotype).(e)Insulincontentinisletsisolatedfrom(1/1)and(2/2)mice.(f)Insitu
pancreatic perfusion in chemerin (2/2) mice. Insulin release was measured from perfused pancreata of (1/1) and (2/2) mice after the indicated
stimuli. (n55–6/genotype). (g) The amount of insulin released (area under the curve [AUC]) after stimulation with 16.7 mM glucose. The AUC was
significantly decreased in chemerin (2/2) pancreas. (h) The AUC was significantly decreased in chemerin (2/2) pancreas after KCl stimulation. (i)
ImmunohistochemicalanalysisofChemR23inMIN6cells.(j)KnockdownofchemerinorChemR23inMIN6cells.(k)GSISwassignificantlyreducedin
chemerin- and ChemR23-knockdown MIN6 cells.
www.nature.com/scientificreports
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factor that is essential for b-cell function
18. Intriguingly, MafA-
deficient mice exhibit glucose intolerance, impaired GSIS with nor-
mal insulin content and reduced expressions of Glut2 and Pdx1 in
the islets
19, thus displayng a striking similarity with chemerin (2/2)
mice, which exhibited impaired GSIS with normal insulin content
andreduced expression of MafA and Glut2. The functional rescue of
GSISbyMafAexpressionusingadenovirusinchemerin(2/2)islets
and chemerin-ablated MIN6 cells indicates that chemerin regulates
b-cell function at least in part by maintaining MafA expression.
However, the rescue of GSIS by MafA was partial, suggesting the
existence of other mechanisms.
MafA expression is regulated bothat the transcriptional and post-
translational levels
20. It has been reported that oxidative stress
induced by hyperglycemia decreases MafA expression
21,22.T o
exclude the possibility that the reduced MafA expression was due
tohyperglycemia-inducedoxidativestress,weanalyzedtheoxidative
stress status in chemerin(2/2) islets; however, there were no
changes in the oxidative stress status (data not shown). In addition,
the results from MIN6 cells suggest a direct regulation of MafA
expression bychemerin. The reduction in MafA mRNA inchemerin
(2/2) islets suggested that chemerin may regulate MafA transcrip-
tion. Therefore, we examined whether chemerin stimulated trans-
criptional activity of the MafA promoter in MIN6 cells; however, an
obvious stimulatory effect on transcriptional activity was not
observed (data not shown), suggesting that chemerin may regulate
the stability of MafA mRNA.
Recently, it has been reported that not only ChemR23, but the
orphan G-protein coupled receptors, CCRL2 and GPR1, also serve
as chemerin receptors. ChemR23-deficient mice were unresponsive
tochemerinwithrespecttoanti-inflammatoryeffects,indicatingthat
ChemR23is essentialfor chemerin function
7,8.Incontrast, chemerin
binds to CCRL2 but does not transduce a signal into cells
9, and
chemerin-induced Ca mobilisation via GPR1 is much weaker than
that of ChemR23
10. In this study, we have shown that ChemR23 is
expressedinb-cells,andthattheablationofChemR23inMIN6cells
Figure 5 | Effects of HFD on chemerin-deficient mice and GSIS in chemerin-transgenic mice. (a) Body weights of chemerin (1/1) and (2/2) mice
after HFD. Body weights were determined 6 weeks after high-fat diet feeding from 8 weeks of age. (n 5 5-8/genotype). (b) Intraperitoneal glucose
tolerance testafter 8weeks ofHFD in (1/1) and (2/2) mice. (n 5 5/genotype). (c)Serum insulin levels after glucose administration followingHFD in
(1/1) and (2/2) mice. (n 5 5/genotype). (d) Characterization of SAP promoter-driven chemerin transgenic mice. Serum (5 mL each) from Tg1, Tg2,
wild-type, and chemerin (2/2) mice was subjected to immunoblotting analysis for chemerin. (e) Quantification of serum chemerin concentrations in
chemerintransgenicmice.(f)Intraperitonealglucosetolerancetestin12-week-oldchemerintransgenicandwild-typemice.(n55/genotype).(g)Serum
insulin levels after glucose administration in chemerin transgenic and wild-type mice. (n 5 5/genotype).
www.nature.com/scientificreports
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the phenotype of chemerin-ablated MIN6 cells. These data suggest
that in b-cells, ChemR23 may be the main receptor for chemerin.
Ontheotherhand,GPR1expressionbutnotCCRL2,wasdetectedin
the islets, suggesting a potential role of GPR-1 as chemerin receptor
in b-cell function.
Several groups have shown that chemerin is an adipokine
11–14 that
regulates adipocyte differentiation and lipolysis in autocrine and
paracrine fashion
11,13. Chemerin expression and secretion increase
dramatically during adipogenesis, andloss of chemerin or ChemR23
expression in pre-adipocytes impairs their differentiation into
matureadipocytes.Inthepresentstudy,wedidnotdetectsignificant
difference in the body weight or the weight of epididymal fat pad
at least until 12 weeks of age. Interestingly, serum NEFA levels
were lower in chemerin (2/2) mice. These results are in line with
previous findings that the absence of chemerin results in reduced
basal and IBMX-stimulated lipolysis rate in 3T3L1 adipocytes
in vitro
11. It is noteworthy that, although the expression of adipocyte
Figure 6 | MafA is regulated by chemerin and rescue of MafA expression in chemerin-deficient islets or chemerin-knockdown MIN6 cells restores
GSIS. (a) MafA and Glut2 mRNA levels were significantly lower in the islets from 12–14-week-old chemerin (2/2) mice than in those of (1/1) mice.
(n 5 5–6/genotype). (b) MafA protein expression was downregulated in chemerin (2/2) islets. (c) Quantitative analysis of MafA protein expression
inislets from 12–14-week-old chemerin (1/1) and(2/2) mice. (n 53/genotype). (d)Immunohistochemical analysis of MafA expression inchemerin
(1/1)and(2/2)islets.Similarresultswereobtainedfromthreeindependentexperiments.Representativeresultsareshown.(e,f)MafAmRNA(e)and
protein (f) expression were downregulated in chemerin- and ChemR23- knockdown MIN6 cells. (g) Rescue of MafA expression in isolated islets using
MafA expressing adenovirus. Islets were infected withcontrol (LacZ) or MafA adenovirus at aMOI of125.(h) The impaired GSIS in chemerin-deficient
islets was partially restored by exogenous MafA expression. Similar results were obtained from 3 independent experiments. Representative results are
shown (age, 10–15 weeks; n 5 3/genotype). (i) Rescue of MafA expression in chemerin-knockdown MIN6 cells infected with control (LacZ) or MafA
adenovirus at a MOI of 8. (j) The impaired GSIS in chemerin-knockdown MIN6 cells was restored by exogenous MafA expression (n 5 6).
www.nature.com/scientificreports
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expression of macrophage markers, CD68 and F4/80, and the
accumulation of macrophages in adipose tissue were reduced in
chemerin (2/2) mice. Given that chemerin is a chemoattractant
like other chemokines for DCs and macrophages
6,23, these data sug-
gest that chemerin plays an important role in the accumulation of
macrophages in adipose tissue. A recent study has shown that
inflammation of adipose tissue caused by an accumulation of
immune cells, including macrophages, plays an important role in
obesity-induced metabolic dysfunction
24. In chemerin (2/2) mice,
irrespective of the reduced macrophage infiltration, glucose
tolerance deteriorated, indicating that the effect of adipose tissue
on the glucose intolerance may be small under this condition.
With respect to the role of chemerin in insulin signaling, in vitro
studies have provided conflicting results; one study reported a
decrease in insulin-stimulated glucose uptake in long incubation
time
25, whereas another study showed an increase in insulin-stimu-
lated glucose uptake and insulin receptor substrate-1 tyrosine phos-
phorylation in shorter incubation time with chemerin treatment in
adipocytes. In primary human skeletal muscle cells, chemerin treat-
mentinducesinsulinresistance
15.Indb/dbmice,chemerintreatment
exacerbates glucose intolerance, by decreasing serum insulin levels,
reducing adipose tissue glucose uptake and decreasing in liver and
total tissue glucose uptake; however, these effects were not observed
in normal mice
16. In this study using glucose clamp studies, we have
clearly shown that chemerin (2/2) mice demonstrate enhanced
insulin sensitivity in the muscle and increased glucose production
in the liver. Total insulin sensitivity, demonstrated by glucose infu-
sion rate, was comparable in chemerin (2/2) and (1/1) mice sug-
gesting that the different modes of action in the muscle and liver
counterbalance each other at least under this condition. The muscle
results of glucose clamp studies and of insulin-induced Akt phos-
phorylation are in line with previous report showing that chemerin
treatment induces insulin resistance in vitro in human skeletal mus-
cle
15. The adipose tissue study showing that a decrease in insulin-
inducedAktphosphorylationiscompatiblewithpreviousreportthat
chemerin treatment enhances insulin sensitivity in 3T3L1 adipo-
cytes
14. Taken together, chemerin plays different roles in the muscle,
adipose tissue, and liver in the context of insulin action.
In summary, although further investigation is required to clarify
the precise role of chemerin in the pathogenesis of diabetes, the
findings herein present a physiological function of chemerin in glu-
cose homeostasis in mice. The present study also demonstrated that
chemerinplaysanimportantroleintheregulationofb-cellfunction.
Methods
Mice andin vivo experiments. Mouse experiments wereperformed according tothe
guidelines of the Animal Ethics Committee of Kobe University Graduate School of
Medicine. Targeting strategy for disruption of the chemerin gene locus is depicted in
Supplementary information. Chemerin transgenic mice were generated using the
human chemerin cDNA under the controlof liver-specific SAP promoter, which was
a generous gift from Dr Miyazaki (Osaka University). Mice were maintained on a
12h/12h light/dark cycle and ad libitum access to food and water. The results pre-
sented here are of studies conducted on mice backcrossed at least for six generations
withC57BL6backgroundand7-15-week-oldage-matchedmice,unlessspecified.For
HFDstudies,8-week-oldmaleC57BL/6Jmicewerefedwithadietcontaining45%fat,
10% protein, and 35% carbohydrates (Oriental Bioservice, Japan) for 6 weeks.
Glucose measurements and intraperitoneal glucose tolerance test. For the
intraperitoneal glucose tolerance test, 50% glucose (1.5g/kg body weight) was
intraperitoneally injected after 15-h fasting. Blood was collected from the tail vein at
0, 30, 60, 90, and 120 min after the injection.
Euglycemic hyperinsulinemic clamp Studies. Euglycemic hyperinsulinemic clamp
studies were performed as previously described
26. Details are presented in
Supplementary information.
Islet morphometry, immunohistochemistry, and immunofluorescence. The
pancreas was isolated, fixed in 4% paraformaldehyde and embedded in paraffin.
Consecutive4mmsectionswerecutandmountedonslides.Thepercentisletareawas
quantified using Image J software, as described previously
27,28.
Immunohistochemistry and immunofluorescence were performed as previously
described
29. Anti-swine insulin antibody was obtained from DakoCytomation
(Denmark). Anti-ChemR23, GPR1, CXCL2, and Mac3 antibodies were from
SantaCruz (CA, USA), anti-MafA antibody was from Bethyl (Tx, USA).
Quantitative real time PCR and immunoblotting. Quantitative real-time PCR
(QRPCR) was performed as previously described
26,30, on a LightCycler system using
the FastStart DNA Master SYBR Green I kit (Roche Diagnostics, Switzerland). Each
value was normalized to 36B4 or b- actin expression. The primer sequences are
provided in Supplementary information. Immunoblotting analysis was performed as
previously described
31.Anti-chemerin and ChemR23 antibodies have beendescribed
previously
14. Anti-Akt, p-Akt (Ser473) antibodies were from Cell Signaling Tech
(MA, USA).
Islet isolation and batch incubation. Mouse pancreatic islet isolation and batch
incubation were performed as previously described
32.
Perfusion of mouse pancreata. Overnight (12–16 h)-fasted mice at 8–15 weeks of
age were used in perfusion experiments as previously described
33. Details are pre-
sented in Supplementary information.
MIN6 cells and knockdown of chemerin and ChemR23. The mouse b-cell line,
MIN6 was cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing
25 mM glucose and 15% (v/v) heat-inactivated fetal calf serum under humidified
conditionsof5%CO2,95%airat37uC
34.ForchemerinandChemR23knockdownsof
in MIN6 cells, the shRNA expression vector, pcPURm6i
35 containing the target
sequenceformousechemerinorChemR23wastransfectedintoMIN6cellsbyreverse
transfection using Lipofectamine 2000 reagent (Invitrogen) as previously
described
36,37.
Infection of the islets and MIN6 cells with Adenovirus. Mouse MafA cDNA
(obtained by RT-PCR) was cloned into pENTR vector (Invitrogen). Adenoviruses
were generated using ViraPower Adenoviral Expression System (Invitrogen),
according tothe manufacturer’s instructions. Cellswere infected withthe adenovirus
for 48 h. Adenovirus expressing lacZ was used as a negative control. The multiplicity
of infection (MOI) for the islets and MIN6 cells were 125 and 8, respectively. The
expression of MafA was verified in mouse embryonic fibroblasts (MEF) and MIN6
cells by immunoblotting (Supplementary Fig. 4e).
Statistics and data analysis. Results are presented as mean6SEM from at least 3
independent, unless stated otherwise. The data were analyzed using unpaired two-
tailed Student’s t test, analysis of variance (ANOVA), or Mann-Whitney U-test as
appropriate. A P value of less than 0.05 was considered significant.
Detailed experimental procedures are provided in Supplementary methods.
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